Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 6, 2007, Pages 808-814

  Nakazawa, Gaku ^a   Tanabe, Kengo ^a   Aoki, Jiro ^a   Yamamoto, Hirosada ^a   Higashikuni, Yasutomi ^a   Onuma, Yoshinobu ^a   Yachi, Sen ^a   Nakajima, Hiroyoshi ^a   Hara, Kazuhiro ^a  

^a MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Percutaneous coronary intervention; Quantitative coronary angiography; Restenosis

Indexed keywords

CREATININE; HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; ROTATIONAL ATHERECTOMY; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249893395     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21016     Document Type: Article

References (24)

1. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.
2. Naidu SS, Selzer F, Jacobs A, Faxon D, Marks DS, Johnston J, Detre K, Wilensky RL. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol 2003;92:1160-1164.
3. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-305.
4. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966-2972.
5. Lemos PA, Arampatzis CA, Hoye A, Daemen J, Ong AT, Saia F, van der Giessen WJ, McFadden EP, Sianos G, Smits PC, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005;95:167-172.
6. Kuchulakanti PK, Torguson R, Chu WW, Canos DA, Rha SW, Clavijo L, Deible R, Gevorkian N, Suddath WO, Satler LF, et al. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2006;97:792-797.
7. Aronow WS, Ahn C, Mercando AD, Epstein S. Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function. Am J Cardiol 2000;86:1142-1143, A9.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (Suppl 1):S1-266.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
11. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
12. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-2278.
13. Azar RR, Prpic R, Ho KK, Kiernan FJ, Shubrooks SJ Jr, Baim DS, Popma JJ, Kuntz RE, Cohen DJ. Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol 2000;86:485-489.
14. Marso SP, Gimple LW, Philbrick JT, DiMarco JP. Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events in patients on chronic hemodialysis. Am J Cardiol 1998;82:378-380.
15. Martinez-Castelao A, Gorriz JL, Garcia-Lopez F, Lopez-Revuelta K, De Alvaro F, Cruzado JM. Perceived health-related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA study). J Nephrol 2004;17:544-551.
16. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine, 16th ed. New York: Mc-Graw-Hill; 2005. pp 1663-1667.
17. Tsutsui M, Shimokawa H, Tanaka S, Yoshihara S, Higuchi S, Matsuguchi T, Okamatsu S. Granulocyte activation in restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 1996;60:27-34.
18. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T, Era S. Oxidative stress is enhanced in correlation with renal dysfunction: Examination with the redox state of albumin. Kidney Int 2004;66:1988-1993.
19. Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL, Sheih SD. Cytokine production during hemodialysis: Effects of dialytic membrane and complement activation. Am J Nephrol 1996; 16:293-299.
20. Schettler V, Wieland E, Methe H, Schuff-Werner P, Muller GA. Oxidative stress during dialysis: Effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Nephrol Dial Transplant 1998;13:2588-2593.
21. Horl WH, Steinhauer HB, Schollmeyer P. Plasma levels of granulocyte elastase during hemodialysis: Effects of different dialyzer membranes. Kidney Int 1985;28:791-796.
22. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, Stone GW. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV trial. Am Heart J 2005;150:1163-1170.
23. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
24. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645.